Clinical Trial Update: Patiromer Efficacy to Reduce Episodic Hyperkalemia in End Stage Renal Disease Patients [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating whether patiromer reduces episodic hyperkalemia in patients with end-stage renal disease. Results were posted on 2025-05-30.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease
• Hyperkalemia

Drugs mentioned

• Veltassa (patiromer)

Snippet

Sponsor: Duke University | Conditions: Hyperkalemia, End Stage Renal Disease | Phase 4 | Status: COMPLETED | Results posted: 2025-05-30